Paul Tudor Jones’s Cidara Therapeutics CDTX Stock Holding History

Paul Tudor Jones’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-44,307	Closed	-$9.79M	–	3677
2025 Q4	$9.79M	Buy	44,307 +29,363	+196%	+$4.75M	0.02%	756
2025 Q3	$1.43M	Buy	14,944 +4,033	+37%	+$257K	﹤0.01%	2023
2025 Q2	$531K	Buy	+10,911	New	+$262K	﹤0.01%	2560

Paul Tudor Jones's CDTX Position: Q1 2026 in Review

Paul Tudor Jones sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 44,307 shares — an estimated $9.79M sold.

Paul Tudor Jones first reported a position in CDTX in Q2 2025 and held it in 3 quarters. The position peaked at $9.79M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Paul Tudor Jones reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Paul Tudor Jones sold 44,307 Cidara Therapeutics shares in Q1 2026, an estimated $9.79M.
Paul Tudor Jones first reported a position in Cidara Therapeutics in Q2 2025 and held it in 3 quarters.
Paul Tudor Jones's Cidara Therapeutics position peaked at $9.79M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.